Selected drugs from the preclinical drug pipeline are tested in innovative clinical trials. We have investigated an FDA-approved compound belonging to a new class of latency-reversal agents discovered at EHEG in a pioneering randomized clinical trial (LUNA), as first and currently only center in the Netherlands doing shock and kill interventional studies.

 

Additional clinical studies are being planned, and options for (inter)national collaboration are engaged. In addition we have tested therapeutic vaccine approaches to improve the HIV-specific cellular immunity in HIV-infected persons, to help eliminate HIV-infected cells.